Concenter Biopharma is working on a novel drug to eliminate type 2 diabetes with no side effects. The drug dramatically lowers insulin resistance, the major cause of T2D, while lowering the body’s chronic and systemic inflammation levels.
“While the majority of type 2 diabetes drugs deal with the symptoms and complications of T2D by removal of the sugar from the blood, they do not address the core of the problem, which is insulin resistance. Our drug is the only one that addresses the cause of the disease, by suppressing insulin resistance (by over 90%, thereby restoring insulin resistance to almost normal) while returning cellular sensitivity to insulin. Furthermore. the drug is without side effects.”, stated Dror Chevion, CEO, Concenter Biopharma.
The company will be doing another round of funding during 2020 given the promising results with animal-model trials as well as the FDA green light to carry out clinical trials. In animal trials, the drug was shown to remove insulin resistance to normal levels in diabetic animals, with a return to healthy blood sugar levels. The company is confident that its drug can be introduced to the market within three years utilizing a “shortcut” regulatory pathway already agreed to by FDA. The drug has been the focus of over twenty years of research by the team of scientists from the Medical School at the Hebrew University of Jerusalem, headed by Prof Mottie Chevion, the Chief Scientific Officer.
“The drug developed by the company is based on patented novel new chemical entity. The Mechanisms of Action of the drug work synergistically with one another to address the strong inflammatory state associated with T2D, through chelation (removal of free iron radicals from tissues and from within cells and at the same time “placement” of a zinc ion into the damaged cells and organs” explained Prof. Chevion.
Prof. Dr. Peter Nawroth (MD), awardee of the 2018 Camillo Golgi Prize – a Prize for outstanding contributions in the field of the histopathology, pathogenesis, prevention, and treatment of the complications of diabetes mellitus and Prof. Ralph DeFronzo (MD), one of the global key opinion leaders in the field of T2D, recently joined Prof. Itamar Raz (MD), the global leader in Diabetes, on Concenter BioPharma’s Scientific Advisory Board.
Prof. DeFronzo, is directly responsible for many of the advances achieved in T2D over the last 50 years. He was a leader in developing the concept of insulin resistance, the defining characteristic of Type 2 diabetes, resulting in novel ideas about the development and progression of diabetes. DeFronzo led the U.S. development of metformin, the first-line medication for treatment of diabetes, and ushered it through FDA approval in 1995.
Diabetes is a complex disorder, consisting of two types: type 1, comprising approximately 5 – 10% of patients, and type 2, comprising 90% – 95%. The prevalence of diabetes, especially type 2 diabetes mellitus (T2D), is rising in the developed world and is associated with increased prevalence of obesity, in particular, in vulnerable minorities, and the aged. T2D is characterized by the combination of insulin resistance, largely due to obesity, and deficient insulin secretion, which appears to be the rate-limiting step in its pathogenesis. Insulin secretion is insufficient under a given degree of insulin resistance and is termed relative insulin deficiency. The cause of the insulin secretory defect is probably multifactorial but is usually considered to be metabolic and not autoimmune driven. The derangements in carbohydrate metabolism in diabetes are clinically recognized when plasma glucose elevations reach levels that cause glycosuria and polyuria with resultant polydipsia.
The initial recommended approach of management of T2D includes lifestyle changes and monotherapy (usually with metformin). If the HbA1c goal has not been met within ~3 months of the initial therapy, then treatment would be intensified by adding a second agent. Glycemic control should be re-assessed again in ~3 months, and triple therapy should be considered if the HbA1c target had not been achieved. Then, a combination of injectable therapy including basal insulin may be considered to obtain adequate glycemic control. In patients with high baseline HbA1c levels, an initial treatment with dual combination therapy can be considered.
There is no “real” cure or even an efficient treatment for T2D, not for now and neither for the near future! For most patients, the disease worsens with time and the treatments “progress” from Monotherapy to Dual Therapy to Triple Therapy to a Combination of Injectable Therapy. In addition to the therapeutically beneficial activities – all the currently employed drugs cause significant side effects. There is yet to be invented a new drug that its use will be associated with minimal (and possibly devoid of) side effects.
Diabetes is a global epidemic. One of three people, globally, is either of diabetic or is pre-diabetic. Overall there are about 463 Million people with diabetes in the world in 2019, expected to grow to 700 Million by 2045. The estimated cost of treating diabetes per year is over 850 billion dollars. In the USA, there are 31 million diabetics and another 90 million pre-diabetics.
For more information: info@concenterbiopharma.com
